New stock news | Dadebio first files for listing on the Hong Kong Stock Exchange to deepen its presence in the field of weight management.

According to the disclosure of the Hong Kong Stock Exchange on September 19th, Hangzhou Xianwei Da Biotechnology Co., Ltd. - B (referred to as Xianweida Biological) has submitted a listing application to the main board of the Hong Kong Stock Exchange, with Morgan Stanley and CICC as joint sponsors. According to the prospectus, Xianweida Biological is a biopharmaceutical company approaching the commercialization stage, dedicated to meeting the urgent medical needs in the field of weight management. The company is about to launch Enoglutide Injection (XW003) in China, the company's core product, which is expected to be the world's first cAMP-biased GLP-1 receptor agonist for the treatment of overweight/obesity and type 2 diabetes. According to the clinical data disclosed by Xianweida Biological, Enoglutide Injection (XW003) achieved a placebo-adjusted weight reduction effect of 15.1% (average weight loss of 17.6% in females) in Chinese overweight/obese patients, superior to Semaglutide (8.5%), and achieved the efficacy of Liraglutide at a lower dose (2.4mg vs 15mg). According to Frost & Sullivan data, weight management and obesity-related complications are the fastest growing urgent medical needs globally. The global weight management drug market is large and steadily growing, expected to grow from $112.8 billion in 2024 to $165.9 billion in 2029. In the weight management industry, obesity and related diseases cover different types of obesity based on patient BMI and age, as well as various weight-related complications such as metabolic dysfunction-related fatty liver disease (MAFLD) and obstructive sleep apnea (OSA). The global overweight/obesity drug market has strong growth potential, with the market expected to expand to $41.7 billion by 2029, with a compound annual growth rate of 19.8% from 2024. Financially, for the six months ended June 30, 2025, the company achieved revenue of RMB 91.067 million; research and development expenses for 2023, 2024, and the six months ended June 30, 2025 were RMB 456 million, RMB 284 million, and RMB 65.027 million respectively. In addition, there were also other operating expenses (including administrative expenses). Therefore, the company recorded net losses in each year/period of the historical performance period.